Research has demonstrated that technologies to support diabetes self-management for people living with type 1 diabetes (T1D) can have positive effects on medical and quality of life outcomes. 1 It also shows that there may be an additional burden of wearing and using these technologies. 1 The psychosocial impact of living with diabetes is complex and impacts both the person with T1D and the people that live with and support them. Experiencing hypoglycemia, for example, is challenging for both the individual with diabetes and the individual's family members, with family members reporting not knowing what to do or what is happening. 2 645365D STXXX10.1177/1932296816645365Journal of Diabetes Science and TechnologyBarnard et al
It is well established that diabetes and its treatment can impact the lives of people living with somebody with T1D in both positive and negative ways. 1 Continuous knowledge of glucose levels with an accurate, discrete device has been cited as a research priority by people with T1D, 3 although CGM has been shown to be beneficial for self-management there are also limitations. Specifically, improvements in glucose control are dependent on consistent CGM use however this is expensive and not always reimbursed by insurance or other health care providers. Furthermore, alarm fatigue, technical failure, and accuracy problems limit ongoing engagement, with lack of trust in the devices and irritation with technological failure cited as primary reasons. A negative psychosocial impact of CGM use has been described, 4 and despite a high proportion of pump use, CGM use in the T1D Exchange cohort remains low with 6% of children <13 years old, 4% of adolescents 13 to <18 years, 6% of young adults 18 to <26 years, and 21% of adults ≥26 years using CGM. Discontinuation rates are high, however, at 41% of users having discontinued use by 1 year. 5 Currently, there is limited research on the impact of diabetes technologies on the lives of those people who live with someone with T1D and their role in helping them to support that person. The aim of the present survey was to explore the perceived impact of diabetes-related technology from the perspective of family members and partners of individuals with T1D, including impact of devices on the life of the individual with T1D and family members, diabetes-related burden, impact on mood and well-being of family members and impact of technology on frequency/severity of hypoglycemia, and diabetes control.
Methods and Participants
Partners and caregivers of people with T1D were invited to complete an online questionnaire about their experiences with diabetes technologies. Questions included a mix of existing validated measures (Problem Areas in Diabetes Short Form , World Health Organization Well-Being Index [WHO-5]) and specific questions exploring the impact of technology. The survey was hosted on T1D Exchange's online patient community, Glu (myGlu.org). All study materials were approved by the Institutional Review Board at the Jaeb Center for Health Research (Tampa, FL). Each participant provided informed consent before participating in the study. The questions were developed by the multidisciplinary research team including medics, psychologists, statistician and family members living with T1D, prior to piloting with potential participants. Minor revisions were made in line with feedback prior to "going live."
Emails were sent to registered Glu members who previously indicated a preference to be contacted about research studies. In addition, information about the study was provided on Glu, Facebook, and Twitter. Eligible participants were required to be at least 18 years old. For the partner survey, participants were required to be living with their spouse, partner, or significant other with T1D. For the parent survey, participants were required to have a child with T1D under the age of 18.
The study was conducted in accordance with the Declaration of Helsinki.
Quantitative responses were analyzed using SPSS software (IBM SPSS Statistics for Windows, Version 23.0) and free-text responses were analyzed using thematic coding and content analysis. Free-text data were analyzed using constant comparison methodology with 2 researchers independently analyzing and coding the text, before consensus was reached on key themes and findings.
Results
Participant demographics and use of diabetes technology are presented in Tables 1 and 2. One hundred parents/caregivers took part as well as 74 partners. Mean duration of living with a person with T1D was 16 ± 13 years for partners, with mean duration of diabetes for children being 4.2 ± 3.2 years. Mean duration of current therapy was 8.3 ± 7.3 years for adults and 3.4 ± 2.9 years for children.
Some parents/caregivers reported dual use of injections using a syringe and an insulin pen In addition, 62% (n = 46) of partners and 66% (n = 66) of parents/caregivers reported current CGM use (up to 7 days a week) by their partner or child. Number of days wearing a CGM had a reported mean of 6.31 ± 1.8 by partners and 6.53 ± 1.1 by parents/caregivers. Tables 3 and 4 present data on the impact of diabetes technology on participants' lives and the lives of their family member. Impact of each device, on both the person filling out the survey and the impact on their family member with T1D was reported on a scale of -2 (extremely negative) to +2 (extremely positive). Partners reported that devices had a less positive impact on their own lives than on the person living with T1D. This was true for use of insulin pumps (effect on self, mean = 1.3 ± 0.8, effect on partner with T1D, mean = 1.7 ± 0.6; t[69] = -3.9, P < .001) and CGMs (effect on self, mean = 1.1 ± 1.2, effect on partner with T1D, mean = 1.4 ± 0.9; t[57] = -3.3, P < .01).
Impact of Device Use on Partners and Parents Compared to Their Family Members With T1D
Parents, on the other hand, reported that pump use benefitted both themselves and their child equally (mean parents = 1.8 ± 0.5, mean children = 1.8 ± 0.5, p = ns), and that CGM use was more beneficial to themselves than their child (mean parents = 1.6 ± 0.8, mean children = 1.0 ± 1.2, t[72] = 5.6, P < .001). When comparing partners to parents, there was a significant difference in the impact of both insulin pump (t[153] = 4.6, P < .001) and CGM use (t[130] = 3.1, P < .01). In both cases, parents report a more positive impact of device use on their own life than partners (means reported above).
In response to whether glycemic control had changed due to their use of diabetes technology, 86% (n = 64) partners and 82% (n = 82) parents/caregivers said that it had made it easier to achieve blood glucose targets. Table 5 shows frequency and severity of hypoglycemia.
Psychosocial Impact of T1D on Family Members
Perceived burden was scored on a 5-point Likert-type scale ranging from no burden (0) to very large burden (4). Parents reported higher perceived burden (mean = 2.2 ± 1.3) than partners (mean = 1.2 ± 1.1; t[184] = 5.7, P < .001).
Negative emotions were measured on the PAID-5, and this scale had good internal consistency (Cronbach's α = .84). Overall, participants reported a relatively low degree of negativity related to diabetes (mean = 31.24 ± 21.8, range 0-100). However, parents reported more negative emotions related to diabetes on the PAID-5 scale than partners (mean = 36.4 ± 22, versus mean = 25.4 ± 20.1; t[187] = 3.55, P < .001; see Figure 1 ).
The WHO-5 was used to obtain an index of well-being, with higher scores indicative of greater emotional stability. This scale had good internal consistency (Cronbach's α = .89), and scores were mostly in the midrange of the scale (mean = 55.3 ± 21.0). Overall, 87% (n = 64) of partners and 66% (n = 66) of parents/caregivers rated their own quality of life as good over the past 2 weeks as assessed by the WHO-5. 6 In all, 5% (n = 4) of partners and 11% (n = 11) of parents/ caregivers reported their quality of life as poor or very poor. Parents reported significantly poorer well-being than partners (mean = 48.7 ± 21.2 versus mean = 62.7 ± 18.7, P < .001; see Figure 1 ). Scores on the PAID-5 and WHO-5 were correlated for both parents (r = -.46, P < .001) and partners (r = -.35, P < .01), indicating that those who had decreased well-being also reported a higher frequency of negative emotions related to their loved one's diabetes.
Impact of Technology on Sleep
Disrupted sleep was commonly reported with 73% of parents/caregivers and 59% of partners reporting waking because of diabetes technology. Of these, 54% of parents/ caregivers and 12% of partners reported waking at least 4 times a week. The main reasons reported were CGM alarms (38% parents/caregivers, 36% partners) and fear of hypoglycemia (19% parents/caregivers, 4% partners). False alarms were uncommon with 26% and 23%, respectively, reporting rare false alarms; however 10% of parents/caregivers and 9% of partners reported false alarms occurring more than once a week. Interestingly, participants report the impact of diabetes technology for their partner/child as generally positive.
Open Questions
Reported involvement in partner's diabetes management did not appear to vary irrespective of duration of diabetes, gender or diabetes-related complications according to the freetext responses. The tables in the online appendix present data on impact of diabetes technology on lived experience, daily functioning, nocturnal waking and satisfaction with training provided for device use.
Free-text responses were coded into key themes, based on how participants reported helping their loved one with T1D. Key themes, listed in order of frequency of occurrence, were the following:
-Reminders and monitoring -Practical support, such as ordering supplies, delivering insulin boluses if BG levels were high, booking medical appointments, and counting carbohydrates -Nocturnal BG testing (parents/caregivers) Insulin pump n (partners = 58, parents/caregivers = 85); CGM n (partners = 50, parents/caregivers = 73); combined n (partners = 13, parents/caregivers = 13); BG meter n (partners = 69, parents/caregivers = 96); 2 partners also report artificial pancreas impact, 1 was neutral and the other extremely positive. 
Discussion
Unsurprisingly, there was a high use of CGM in both groups-partners and parents/caregivers with a high number of male partners participating. This finding is consistent with reported CGM use within the Glu community, in which 64% of people who provided this information were current or former CGM users.
There was a considerable difference in perceived burden of diabetes management support for partners versus parents/ caregivers. Again this is perhaps unsurprising considering that parents/caregivers take responsibility for a younger child's diabetes management rather than simply providing support. There was a broad range of involvement in the partner's diabetes care which may point to factors such as personality characteristics of the respondent and/or the partner living with T1D Interestingly, not all participants reported currently using a standard BG meter, however this may be a function of it being "taken as given" rather than lack of use. Even with consistent CGM use, a standard BG meter remains necessary for calibration and to confirm glucose readings before dosing insulin. Generally, technological devices were reported as having a neutral or positive impact on participants' lives, however combined insulin pump and CGM devices fared less well.
A reported benefit of insulin pump therapy, CGM, and artificial pancreas use is reduced severity and frequency of hypoglycemia. 7, 8 This outcome was reported by half of participants, who believed their family member experienced fewer hypoglycemic events, and similarly half reported reduced severity of hypoglycemic events. These results could perhaps be attributed to tighter glycemic targets that the technology can facilitate, or perhaps a requirement for greater utilization of the specific features of the technology, for example, temporary basal rates. Most participants reported achievement of glycemic targets to be easier for their partner/child with T1D as a consequence of using diabetes technology.
The ability to target tighter glycemic control, while beneficial medically, may in fact add to the burden of disease management. Diabetes-related distress, including fear, feelings of guilt, anxiety, depression, and being overwhelmed by diabetes management, was commonly reported by both parents/caregivers and partners. The challenge of helping to manage diabetes was reported as a large or very large burden by 45% of parents/caregivers and 11% of partners, which may contribute to the high numbers of participants reporting elevated diabetes-related distress.
Parents/caregivers reported a more negative impact on family relationships than did partners. There was widely reported negative impact on relationships, more so for parents/caregivers than partners. While T1D can be difficult for all family members, parents/caregivers in particular seem to shoulder more of the burden as evidenced by their decreased quality of life. Family conflict is commonly associated with diabetes, 9 as the additional pressure of managing diabetes alongside other daily tasks takes its toll. Regarding impact of technology on sleep and night time alarms, research is ongoing to develop more robust CGM alarm algorithms that will reduce false positive alarm rates by modeling physiology, 10 compensating for frequent perturbations such as pressure. 11 Furthermore, the integration of multiple diabetes technologies, such as automatic dose capture (eg, Smart Pens), more accurate and reliable CGM, 12 and robust physiological algorithms that include insulin on board estimates, 13 is also further expected to increase CGM alarm reliability, reducing intrusiveness and disease reminders.
The strength of the current study is that it is the first study that directly explores family member perspectives of the impact of diabetes technology, which informs potential uptake and sustained successful use thereof. The study is limited however in that it reaches only participants who are members of the Glu community and so may not be representative of the wider diabetes community, for example, Glu membership may be more tech savvy as an online community. That being said, Glu is an open community of persons with T1D, and is one avenue where greater understanding of the disease and supporting improved experiences for those living with T1D is actively pursued. Exploring concerns about accuracy of devices in greater detail would have been useful in terms of explaining whether this is a contributing factor for discontinuation of CGM devices.
It could be argued that the experiences of partners and parents/caregivers are different in terms of levels of responsibility and experience. We would suggest, however, that within these cohorts the experiences of individuals vary hugely, as seen in the results. It is our opinion that there are both similarities and differences between and within the groups, and these are explored from a personal perspective in the current study. This is both a strength and a limitation, and debate is welcomed in this regard.
Conclusions
There is little doubt about the medical benefit of diabetes technologies, and their uptake is increasing. To ensure that such devices are used in a way that returns maximum benefit from a medical and psychological perspective, it is necessary to understand the personal experiences of users and their families. Barriers to uptake of technologies lie beyond the mechanics of diabetes management. Supporting users in using diabetes technology to achieve the best possible glycemic control, in the context of their own life, is crucial.
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